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“Blueberry mufﬁnb a b y ” is a term describing the cutaneous
manifestations of various congenital infections and neoplas-
tic diseases. Especially in infants in whom these cutaneous
ﬁndings are accompanied by severe illness, providers must
rapidly navigate the broad range of possibilities. Here, we
outline the most likely diagnoses with this presentation and
discuss a case of Langerhans cell histiocytosis (LCH) in a
preterm neonate with severe multiorgan involvement.
Keywords
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Abstract Hemorrhagic pustules with a “blueberry mufﬁn” appearance accompanied by respira-
tory failure in a neonate present a challenging differential diagnosis that includes
infections and neoplasms. We present a case of multiorgan, multisite Langerhans cell
histiocytosis (LCH), positive for the oncogenic BRAF V600E mutation, in a preterm
neonate. Infants with LCH pose a diagnostic challenge due to their heterogeneous
presentations. This case is unusual in that the newborn presented with severe multi-
organ involvement. Due to the rare incidence, wide spectrum ofclinical manifestations,
and high mortality rate, clinicians must maintain a high index of suspicion for LCH.
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.Case Report
A 4-day-old preterm male neonate was transferred to the
neonatal intensive care unit (NICU) for evaluation of respira-
tory failure and cutaneous hemorrhagic pustular lesions. The
neonatewas born at 33
2/7 weeks’ gestation at 2,204 g to a 36-
year-old gravida 5, para 2 mother. Maternal prenatal infec-
tious history was negative. Prenatal ultrasounds detected a
singlelesion below thefetus’ left eye that could not befurther
characterized.
The neonate was born via spontaneous vaginal delivery. In
the delivery room, the newborn required intubation and
cardiopulmonary resuscitation due to apnea and bradycardia.
He was subsequently transferred to the NICU. On exam, his
weight and length were at the 75th percentile, with head
circumference at the 25th percentile. Exam revealed multiple
cutaneouslesionsofvaryingsizealloverhisbody,includinghis
oralmucosa,hands,andfeet(►Fig.1A).Thespleentipandliver
edge were both palpable 1 to 2 cm below the costal margin.
Initial laboratory evidence was signiﬁcant for pH 6.6 with
PCO2 86 and HCO3 24, hemoglobin 17 g/dL, WBC 19,000 cells/
μL, platelet count 147,000 cells/μL, Gamma-Glutamyl Trans-
peptidase (GGT) 1,014 U/L, total bilirubin 11 mg/dL, direct
bilirubin 2.5 mg/dL, prothrombin time 15.2 seconds and
partial thromboplastin time 56 seconds. On peripheral blood
smear, mature neutrophils were predominant, and no blasts
were seen. These data were interpreted as showing severe
uncompensated respiratory acidosis, mild erythroblastosis
without evidence of marrow inﬁltration, and hepatic dys-
function leading to coagulopathy.
The newborn was transitioned from conventional me-
chanical ventilation to high-frequency ventilation and devel-
oped a pneumothorax. Upon transfer to a tertiary NICU,
refractory hypoxia and a combined metabolic and respiratory
acidosis persisted despite high-frequency ventilation and the
addition of nitric oxide. A chest radiograph illustrated hyper-
inﬂation and cystic-appearing blebs. The neonate had nega-
tive tests for cytomegalovirus (CMV), herpes simplex virus
(HSV), varicella zoster virus, human immunodeﬁciency virus,
paramyxovirus, toxoplasma, syphilis, parvovirus B19, and
rubella. Placental pathology was consistent with chronic
and focal villitis. The initial microscopic appearance of this
disease process on abdominal skin biopsy was highlyatypical
and suggestive of hematologic malignancy; leukemia cutis
was ﬁrst considered, but immunohistochemistry suggested
LCH. Despite maximal respiratory and cardiovascular sup-
port, the newborn’s condition deteriorated, and care was
redirected toward comfort measures.
The family consented to a full autopsy. External examina-
tion demonstrated diffuse black papules and pustules prefer-
entially involving the hands and feet. Internal examination
revealed disease involvement of multiple sites in the chest
and abdomen. Most striking were the lungs, which appeared
consolidated and contained multiple cavitations and hemor-
rhagic nodules with interspersed normal-appearing paren-
chyma (►Fig. 1B). The thymus was enlarged and friable.
Tumor nodules werefound on the gastrointestinal tract, liver,
pancreas, and adrenal glands. Histologic analysis of the skin
lesions, lungs, thymus, and abdominal tumor nodules dem-
onstrated a histiocytic inﬁltrate with occasional eosinophils
and other inﬂammatory cells. The histiocytes had poorly
deﬁned cell borders and grooved nuclei, and they exhibited
immunohistochemical expression of S100, CD1a, and Lan-
gerin, establishing the diagnosis of multisite, multisystem
LCH. DNA extracted from the lesional tissue was positive for
the BRAF V600E mutation on pyrosequencing.
Discussion
The differential diagnosis of hemorrhagic vesicopustules and
respiratory failure in a preterm neonate can be dichotomized
into infectious and noninfectious etiologies. Congenital in-
fections should always be considered, including those listed
in ►Table 1. CMV and HSV can present with cutaneous
manifestations and systemic illness as presented here, such
as profound respiratory and multiorgan involvement.1 How-
ever, diagnoses like toxoplasmosis or syphilis are unlikely
given the lack of lymphadenopathy.2
In severely ill infants, congenital malignancies should be
the noninfectious diagnoses highest on the differential.
Congenital leukemias, most often acute myelogenous leuke-
mia and occasionally acute lymphocytic leukemia, are the
neonatal cancers most associated with cutaneous manifes-
tations but are unlikely to directly cause lung disease.3
Neuroblastoma and rhabdomyosarcoma can present in
Fig. 1 (A) The skin was diffusely involved by dark, crusted pustules.
(B) The lung parenchyma appeared focally consolidated with cavita-
tions and intervening normal-appearing areas of lung parenchyma.
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.neonates with skin metastases and produce lung tumors,
although these would be unlikely to be cystic.
LCH is a rare, proliferative disease of Langerhans cells,
usuallyaffectingchildren,withanincidenceofﬁvepermillion.4
What was formerly considered a group of distinct histiocytic
disorders, including Hand-Schüller-Christian disease, Letterer-
Siwe disease, eosinophilic granuloma, and histiocytosis X, is
now uniﬁed into a single disease.5 This classiﬁcation emerged
with the discovery that the abnormal cells in all of these
disorders have ultrastructural features and surface antigens
characteristic of Langerhans cells.6–9 Today, LCH is classiﬁed
based on number of sites and organs involved. Single-site
disease isthe mostpredominantand hasafavorableprognosis.
Multisystemdiseasewithoutriskorganinvolvementhasagood
prognosis, whereas multisystem disease involving any risk
organ (lung, liver, or bone marrow) is often fatal.10,11
Infants with LCH pose a diagnostic challenge due to their
heterogeneous presentations. There have been small case
series attempting to correlate clinical ﬁndings with progno-
sis, but results are inconsistent and data are scant. One
retrospective series found that the most common presenting
skin lesions were erythematous, often crusted, and vesiculo-
pustular in nature and, more importantly, that the type of
lesion could not predict the extent of other organ system
involvement.12
Due to the rare incidence, varied presentation, and signiﬁ-
cant potential for mortality, clinicians must maintain a high
index of suspicion for this diagnosis in infants. Because skin
disease is a common presenting feature and the site most
amenable to biopsy, skin biopsy with immunohistochemistry
is crucial. The histologic appearance of LCH is characteristic,
and CD1a staining is speciﬁc for Langerhans cells.13 Impor-
tantly, a majority of infants with cutaneous LCH also have or
go on to develop multisystem disease,14 which must be
diagnosed promptly so that treatment can be initiated. Labo-
ratory tests upon diagnosis should include complete blood
count, liver function tests, and cultures if infectious symp-
toms are present. Bone marrowaspiration and biopsy may be
useful in the evaluation of cytopenias.15 Imaging should
include a chest radiograph, and chest computed tomography
should be obtained if pulmonary symptoms are present. A
skeletal survey and abdominal ultrasound should also be
considered to evaluate for bone involvement and hepatos-
plenomegaly, respectively. Our patient’s workup was limited
due to his physiologic instability.
It is now known that the Langerhans cells in LCH lesions
are biologically distinct from normal Langerhans cells found
in skin.15 Whether LCH is neoplastic or reactive in nature has
been an area of great debate.16,17 A recent study found
somatic mutations in the oncogene BRAF V600E in 57% of
archived cases of LCH, lending support to a neoplastic basis.18
The V600E mutation leads to constitutive activation of the
BRAF kinase, causing cell proliferation and survival. This
mutation is found in a variety of human tumors, most
commonly cutaneous melanoma, although it is also found
in a majority of benign melanocytic nevi, suggesting that
further genetic changes are necessary for malignant transfor-
mation, at least in melanoma.19
Although conventional multiagent chemotherapy is effec-
tive in about 70% of children with high-risk, multisystem
LCH,20 our patient was not a candidate for this type of
treatment at the time of diagnosis due to the presence of
multiorgan system failure. Targeted therapy with BRAF in-
hibitors may soon offer a less toxic alternative, however.
These agents have led to prolonged survival in melanoma
in phase III trials,21,22 and a recent case series reported
sustained responses to vemurafenib in adults with LCH.23
This report is one of only a few in the literature of multi-
systemic LCH in a preterm newborn leading to multiorgan
systemfailureanddeath.It representstheﬁrstpublishedcase
of LCH presenting perinatally to be associated with the BRAF
V600E mutation.
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